The Study
Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network
This study watched what happened to 21 people after they started taking a new diabetes medicine. It saw that some blood markers changed, and some cells acted differently. But it didn’t compare them to people who didn’t take the medicine, so we can’t say the medicine caused those changes—maybe they just happened naturally.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study looked at how a weight-loss diabetes drug called semaglutide affects fat around the heart and immune cells that can clog arteries.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 559 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These changes suggest the drug may lower the risk of heart attacks by reducing fat-related inflammation and preventing blood clots.
- 2After 6 months, people lost 9% of their heart fat, 14% of body fat, and 12% of belly fat.
- 3Their blood showed 21% less FABP4 (a fat-related inflammation marker) and 81% more CD88 (an immune signal).
- 4The drug also made immune cells stick less to blood vessel walls.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cardiovascular Diabetology
Year
2024
Authors
D. García-Vega, D. Sánchez-López, Gemma Rodríguez-Carnero, R. Villar-Taibo, J. E. Viñuela, A. Lestegás-Soto, Ana Seoane-Blanco, María Moure-González, S. B. Bravo, Á. Fernandez, J. González-Juanatey, S. Eiras
Related Content
Claims (6)
In obese adults with type 2 diabetes, semaglutide treatment is linked to a 14% decrease in total fat mass and a 12% decrease in visceral fat, along with lower levels of plasma FABP4 and better metabolic markers.
In obese adults with type 2 diabetes, semaglutide increases the presence of CD88 receptors on neutrophils, which are involved in complement activation and inflammation, suggesting a broader influence on immune regulation beyond reducing inflammation.
In obese adults with type 2 diabetes, taking semaglutide once a week for six months is linked to a 21% decrease in a specific fat-related protein in the blood and an 81% increase in a marker on immune cells called neutrophils.
In obese adults with type 2 diabetes, semaglutide treatment is linked to higher levels of gelsolin protein released from fat tissue around the heart, and this protein is known to reduce blood clot formation.
Semaglutide decreases the sticking of neutrophils to blood vessel lining cells when glucose levels are high, by reducing the amount of CD11b protein on the neutrophils.
Taking semaglutide for 12 months results in a 9% decrease in epicardial fat volume.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.